TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1460184
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (75 mg Zn/day) in bulimics
Study: 1460184
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (75 mg Zn/day) in anorexics
Study: 2866965
Drug: bopindolol 1.35
Approvals — FDA: no, EMA: no, PMDA: no
Description: bopindolol 1.35 mg/day
Study: 2866965
Drug: metoprolol 144
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoprolol 144 mg/day
Study: 2866965
Drug: bopindolol 1
Normalized name: bopindolol 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: bopindolol 1 mg o.d. and 8 mg once weekly
Study: 2866965
Drug: bopindolol long-term
Normalized name: bopindolol
DrugBank: Bopindolol (DB08807)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bopindolol long-term therapy
Study: 2866965
Drug: bopindolol treatment
Normalized name: bopindolol
DrugBank: Bopindolol (DB08807)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bopindolol treatment withdrawal
Study: 30755452
Drug: Imarikiren 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imarikiren 5 mg
Study: 30755452
Drug: Imarikiren 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imarikiren 20 mg
Study: 30755452
Drug: Imarikiren 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imarikiren 40 mg
Study: 14694250
Drug: Continuous Positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Positive Airways Pressure (CPAP) treatment
Study: 14694250
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of CPAP treatment
Study: 9836209
Drug: Midazolam 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.25 mg.kg‐1
Study: 11391326
Drug: Fluticasone nasal
Normalized name: fluticasone nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone nasal spray
Study: 2223156
Drug: Bestatin combination
Normalized name: Nystatin
DrugBank: Nystatin (DB00646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bestatin combination therapy (30 mg daily)
Study: 526384
Drug: i.v. ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. ketamine 2 mg/kg body weight
Study: 371650
Drug: ergometrine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ergometrine 0.5 mg
Study: 526384
Drug: intra-cervical 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: intra-cervical 0.5% lignocaine 20 ml
Study: 30894455
Drug: Lacnotuzumab (0.01-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacnotuzumab (0.01-20 mg/kg)
Study: 30894455
Drug: Lacnotuzumab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacnotuzumab (5 or 10 mg/kg)
Study: 19961377
Drug: Microthreads placed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Microthreads placed at the implant top (group A)
Study: 19961377
Drug: Microthreads placed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Microthreads placed 0.5 mm below the implant top (group B)
Study: 17085674
Drug: Aspirin intervention
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin intervention
Study: 19333080
Drug: Japanese encephalitis
Normalized name: Japanese Encephalitis IM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Japanese encephalitis vaccine
Study: 3540212
Drug: Acyclovir, 45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir, 45 mg/kg/day as a continuous IV infusion for 28 days
Study: 15666120
Drug: Low-dose etidronate
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose etidronate (200 mg daily for 2 weeks followed by 12 weeks of calcium supplementation of 500 mg/day)
Study: 15666120
Drug: High-dose etidronate
Normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose etidronate (400 mg daily for 2 weeks followed by 12 weeks of calcium supplementation of 500 mg/day)
Study: 15666120
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment with osteoactive drugs)
Study: 12897639
Drug: Selegiline 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline 15 mg/day for 3 weeks
Study: 10526278
Drug: Chemotherapy (idarubicin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (idarubicin, methylprednisolone, high dose ara-C)
Study: 8682147
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml kg‐1 of Ringer acetate solution without glucose
Study: 8682147
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml kg‐1 of Ringer acetate solution with 0.5% glucose
Study: 6295132
Drug: Wheat bran
Normalized name: Wheat bran
DrugBank: Wheat bran (DB10685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat bran feeding (0.5 g/kg body weight)
Study: 6295132
Drug: Exercise training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise training (4 mile walk‐jog run program 3 times weekly)
Study: 30900607
Drug: 200 mL
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mL
Study: 30900607
Drug: 250 mL
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mL
Study: 30900607
Drug: 300 mL
Normalized name: HYQVIA 30 GM / 300 ML Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mL
Study: 23008509
Drug: Sustained anticoagulation
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained anticoagulation (warfarin)
Study: 21029995
Drug: HighCPAP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HighCPAP treatment
Study: 21029995
Drug: LowCPAP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: LowCPAP treatment
Study: 12063520
Drug: HFA-BDP (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFA-BDP (200 microg twice daily)
Study: 12063520
Drug: DPI-BDP (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPI-BDP (1000 microg twice daily for 4 weeks)
Study: 9877478
Drug: Liquid oxygen
Normalized name: OXYGEN 99 L in 100 L RESPIRATORY (INHALATION) GAS [Liquid Oxygen]
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liquid oxygen (L)
Study: 7634630
Drug: Ketorolac 60
Normalized name: ketorolac 60 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 60 mg intraoperatively and 30 mg every 8 hours for 5 doses postoperatively
Study: 2224948
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus Nicardipine
Study: 346049
Drug: Prednisone (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (80 mg orally for 2 days)
Study: 346049
Drug: Prednisone with
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone with aspirin
Study: 346049
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with aspirin
Study: 19505878
Drug: Sargramostim 6
Normalized name: Sargramostim
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sargramostim 6 microg/kg subcutaneously once daily
Study: 21518561
Drug: Prophylactic antibiotic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotic use
Study: 1090684
Drug: 1% tolnaftate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% tolnaftate cream
Study: 1303075
Drug: 10% w/w
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% w/w tea tree oil cream
Study: 22552566
Drug: Telmisartan 80
Normalized name: telmisartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 80 mg a day
Study: 22552566
Drug: Ramipril 10
Normalized name: ramipril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 10 mg a day
Study: 18378520
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (ramipril + telmisartan)
Study: 15758247
Drug: Rosiglitazone 4
Normalized name: rosiglitazone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone 4 mg/d for 4 weeks
Study: 11422263
Drug: Imidazolidinyl urea
Normalized name: Imidazolidinyl urea
DrugBank: Imidurea (DB14075)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imidazolidinyl urea (IMID) patch test at concentrations from 0 to 600 microg/cm(2)
Study: 8487648
Drug: Acipimox (500-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox (500-mg capsules)
Study: 3552921
Drug: Propranolol (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (160 mg long-acting per day)
Study: 17551726
Drug: High-energy extracorporeal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-energy extracorporeal shock wave treatment (ESWT; 1,500 shocks at 18 kV, 0.22 mJ/mm(2) without local anaesthesia)
Study: 16899517
Drug: Controlled individualized
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled individualized calcineurin inhibitor exposure
Study: 14986815
Drug: Low daily
Normalized name: SODIUM FLUORIDE 2.43 mg in 1 g DENTAL PASTE, DENTIFRICE [Auraglow Daily]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low daily doses of IFN‐alpha2b (1.5 MU) 'consolidation therapy' for 1 year
Study: 25549483
Drug: Infusion therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion therapy with sodium chloride 0.9%
Study: 25549483
Drug: No infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: No infusion therapy
Study: 18991514
Drug: Nigella sativa
Normalized name: NIGELLA SATIVA SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nigella sativa seed aqueous extract (0.375 mL/kg of 50 g% boiled extract)
Study: 19969339
Drug: Budesonide/formoterol combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol combination therapy
Study: 10027654
Drug: GHB 25
Normalized name: GHB
DrugBank: gamma-Hydroxybutyric acid (DB01440)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHB 25 mg x kg(‐1)
Study: 19733712
Drug: Spot drug-eluting
Normalized name: Cold Spot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spot drug-eluting stenting (spot DES)
Study: 11502527
Drug: Clinafloxacin 200
Normalized name: Finafloxacin
DrugBank: Finafloxacin (DB09047)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clinafloxacin 200 mg
Study: 8777381
Drug: Methimazole (MMI)
Normalized name: Methimazole
DrugBank: Methimazole (DB00763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole (MMI) low-dose regimen starting with 45 mg/day, lowering dose thereafter
Study: 8777381
Drug: Methimazole (MMI)
Normalized name: Methimazole
DrugBank: Methimazole (DB00763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole (MMI) 60 mg/day + levothyroxine
Study: 8777381
Drug: Methimazole (MMI)
Normalized name: Methimazole
DrugBank: Methimazole (DB00763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole (MMI) 30 mg/day + levothyroxine
Study: 1853688
Drug: Intravenous ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ketoprofen 1.5 mg.ml‐1
Study: 1853688
Drug: Pethidine 1
Normalized name: Pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pethidine 1 mg.kg‐1
Study: 27123743
Drug: HBV vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBV vaccine (Engerix-B™, GSK Vaccines, Belgium) administered in 3 doses according to a 0, 1, 6 months schedule.
Study: 22682949
Drug: Sitagliptin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin + Metformin
Study: 15742005
Drug: Rofecoxib 25
Normalized name: rofecoxib 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib 25 mg daily for up to 4 years
Study: 10064664
Drug: Fast feed
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast feed advancement (35 cc/kg/d increments, 5-day schedule to full feeds)
Study: 25296066
Drug: internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: internet-delivered cognitive behaviour therapy (iCBT)
Study: 22901359
Drug: OROS methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS methylphenidate 54-72 mg/d
Study: 17084625
Drug: 2.0% DHEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0% DHEA cream applied twice daily
Study: 16433809
Drug: Placebo applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo applied twice daily
Study: 11801579
Drug: AmBisome (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: AmBisome (3 or 5 mg/kg/day)
Study: 2228983
Drug: Conventional electroconvulsive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional electroconvulsive therapy (ECT)
Study: 528125
Drug: Phentermine resin
Normalized name: phentermine resin
DrugBank: Phentermine (DB00191)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phentermine resin 30 mg for eight weeks followed by placebo for eight weeks (Group 1)
Study: 23536720
Drug: Onartuzumab (MetMAb,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onartuzumab (MetMAb, OA5D5v2) administered i.v. once every three weeks in combination with erlotinib
Study: 23536720
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered in combination with erlotinib
Study: 12903918
Drug: Systemic cephazolin
Normalized name: Cephazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic cephazolin administration (3 g x day(-1) for 5 days) without oral cleansing
Study: 14985668
Drug: Oral phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral phenytoin
Study: 7125336
Drug: Low-dose naloxone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose naloxone (0.8 mg)
Study: 7125336
Drug: High-dose naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose naloxone (10 mg)
Study: 10612553
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate (MgSO4) infusion
Study: 21640839
Drug: Citalopram (SSRI;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (SSRI; selective serotonergic reuptake inhibitor)
Study: 15569338
Drug: Argatroban regimen
Normalized name: Argatroban
DrugBank: Argatroban (DB00278)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Argatroban regimen C: steady-state, 2-microg/kg/min infusion initiated 4 hours before dialysis
Study: 11426017
Drug: High-dose d-penicillamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose d-penicillamine
Study: 9298518
Drug: Amisulpride (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride (800 mg/day)
Study: 7961554
Drug: Clozapine treatment
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clozapine treatment (continued treatment)
Study: 7961554
Drug: Clozapine treatment
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clozapine treatment with plasma concentrations above 350 ng/mL
Study: 3498747
Drug: NSAIDs (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAIDs (specific drugs include indomethacin and naproxen)
Study: 3498747
Drug: NSAIDs (specifically
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAIDs (specifically indomethacin, 150 mg/day)
Study: 2148504
Drug: Methyldopa 250
Normalized name: methyldopa 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyldopa 250 mg twice daily
Study: 27307573
Drug: Chimpanzee adenovirus
Normalized name: COVID-19 VACCINE ADENOVIRUS-26
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chimpanzee adenovirus 63 and modified vaccinia virus Ankara-vectored vaccine expressing a multiepitope string fused to TRAP and 3 doses of RTS,S/AS01B (group 1; n=20)
Study: 27307573
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of RTS,S/AS01B alone (group 2; n=17)
Study: 17710003
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection of bupivacaine and methylprednisolone at intervals of 4 to 5 days
Study: 11496850
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy (nelfinavir plus efavirenz and two nucleoside analogues)
Study: 11496850
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with efavirenz
Study: 25888851
Drug: SrRan 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: SrRan 2 g/day
Study: 24660579
Drug: Seretide (salmeterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seretide (salmeterol 50 µg/fluticasone 250 µg, twice a day)
Study: 10952955
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg folic acid daily for 12 weeks
Study: 9663892
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg folic acid and 4 g betaine daily for 12 weeks
Study: 9481724
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg folic acid daily for 40 weeks
Study: 9481724
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg folic acid daily for 40 weeks
Study: 9481724
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg folic acid daily for four weeks
Study: 8550857
Drug: MOTS CPC
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOTS CPC (6.6 mg cetylpyridinium chloride), 2 x daily for 2 hours intra-orally
Study: 8550857
Drug: Peridex (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peridex (15 ml, 2 x daily for 30 seconds rinsing)
Study: 2677961
Drug: Milk-based diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk-based diet containing 6 g/kg of body weight per day of lactose
Study: 7857040
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no prophylactic antibiotics)
Study: 7040157
Drug: Chlorpromazine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpromazine (1 mg/kg)
Study: 7040157
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (hydration and tetracycline)
Study: 24679880
Drug: Dissolution therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dissolution therapy with potassium sodium hydrogen citrate at a dose of 1 mEq/kg per day for 1 to 3 months
Study: 20491229
Drug: Diode laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diode laser (GaAIAs ‐ 780 nm) applied on the temporalis and masseter muscles, energetic doses of 25 J/cm2 and 60 J/cm2, applied twice a week for four weeks
Study: 11978902
Drug: Risedronate treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate treatment for 3 years
Study: 7642415
Drug: Alternating chemo-radiotherapy
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating chemo-radiotherapy (Cisplatin 20 mg/mq and Methotrexate 40 mg/mq instead of 5-Fluorouracil) with two cycles of 25 Gy/10 fractions/12 days each.
Study: 26124031
Drug: Intrusive force
Normalized name: Clean Force
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrusive force of 250 g (heavy)
Study: 21192139
Drug: Sertraline (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (up to 200 mg daily)
Study: 19581310
Drug: Concurrent three-dimensional
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent three-dimensional conformal radiotherapy (3D‐CRT) and androgen deprivation (AD)
Study: 11535311
Drug: Chromatographically purified
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chromatographically purified rabies vaccine (CPRV)
Study: 11535311
Drug: Human diploid
Normalized name: rabies vaccine, human diploid cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human diploid cell vaccine (HDCV)
Study: 2441535
Drug: sotalol (160‐320
Approvals — FDA: no, EMA: no, PMDA: no
Description: sotalol (160‐320 mg p.o.) + mexiletine (600‐800 mg p.o.)
Study: 22206748
Drug: Pulsatile infusion
Normalized name: PULSATILLA PRATENSIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsatile infusion of oxytocin
Study: 22206748
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of oxytocin
Study: 18602511
Drug: 60 cc
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 cc of gin (18.5 g of ethanol)
Study: 18602511
Drug: 180 cc
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 cc of red wine (18.9 g of ethanol)
Study: 18602511
Drug: Placebo (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (120 cc of water)
Study: 9274547
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (2 g/day of elemental calcium)
Study: 1477851
Drug: Dextromethorphan (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan (60 or 90 mg p.o. q.i.d.)
Study: 26041041
Drug: Bivalent genogroup
Normalized name: Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen / Neisseria meningitidis serogroup B recombinant LP2086 B01 protein variant antigen Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent genogroup 1 genotype 1 (GI.1)/GII.4 norovirus vaccine
Study: 11911356
Drug: Intragastric infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intragastric infusion of Lipofundin S 20% (306 kcal)
Study: 7714309
Drug: Cognitive Behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behaviour Therapy (CBT); Components: cognitive restructuring and assertion training; Population size: 24
Study: 29410318
Drug: 1% diacerein
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% diacerein cream
Study: 25713600
Drug: Donepezil 10
Normalized name: donepezil 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 10 mg
Study: 20335632
Drug: Multi-micronutrient supplement
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-micronutrient supplement (daily dose containing vitamins A, B complex, C, D, E, folic acid, copper, iron, and zinc)
Study: 19689077
Drug: Multi-micronutrient supplement
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-micronutrient supplement
Study: 18242753
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (pelvic muscle exercises plus advice on healthy living)
Study: 29389568
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g of pearl powder/d (n=10)